{"entity":{"id":"luminary-therapeutics","kind":"company","name":"Luminary Therapeutics","aka":["Luminary Therapeutics, Inc."],"tldr":"Luminary Therapeutics is a Minneapolis company making CAR-T cells, immune cells engineered to find cancer, that use the natural BAFF ligand to hit three receptors on B cells at once. Its first product, LMY-920, is in early trials in lymphoma, myeloma and leukaemia.","summary":"Luminary Therapeutics describes itself as a clinical-stage company developing allogeneic cell therapies, with a gamma-delta T cell platform intended to yield many doses from one donor. Its BAFF-L CAR binds three receptors across the B-cell lineage. The lead product LMY-920, an alpha-beta T cell BAFF-L CAR, is listed on its pipeline page in non-Hodgkin lymphoma (NCT05312801, Cleveland Clinic), multiple myeloma (NCT05546723, University Hospitals) and chronic lymphocytic leukaemia, alongside an autoimmune trial. In fiscal year 2026 NCI awarded it USD 586,799 under SBIR award 5R44CA278021-03 for allogeneic BAFF ligand-based CAR-T cells in B-cell malignancies.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.luminarytx.com/"},{"label":"Luminary Therapeutics: pipeline","url":"https://www.luminarytx.com/pipeline/"},{"label":"NIH RePORTER: SBIR award 5R44CA278021-03","url":"https://reporter.nih.gov/project-details/11421504"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","gamma-delta-t-cell-therapy","allogeneic-cell-therapy"],"targets":[],"drugs":["lmy-920"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Patient numbers on the pipeline page are the company's own. Read on luminarytx.com, ClinicalTrials.gov and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"Minneapolis, MN","country":"US","companyType":"cell-therapy","website":"https://www.luminarytx.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":586799,"source":"https://reporter.nih.gov/project-details/11421504","note":"NCI SBIR award (R44) 5R44CA278021-03: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies"}]},"route":"/companies/luminary-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"gamma-delta-t-cell-therapy","kind":"technology","name":"Gamma-delta T cell therapy","route":"/technologies/gamma-delta-t-cell-therapy/"}],"drug":[{"id":"lmy-920","kind":"drug","name":"LMY-920","route":"/drugs/lmy-920/"}]}}